Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy

Press Release

San Francisco, CA – (NewMediaWire) – March 10, 2021 – Oncology Pharma Inc. (OTC: ONPH): Today, the company announced it is putting together a short list of contract research organizations (CROs) to assist in developing a research plan, along with indications for treatment in developing intellectual property towards commercialization.On February 26, 2021 the company announced that it had signed a worldwide license agreement with SYBLEU Inc. for a combination therapeutic platform for treating cancer. A spokesperson for the company stated it is anticipated there will be several indications this therapeutic will be used for in treating various cancers.  It will be the role of the selected CRO to carry out research on behalf of the company.  The selected CRO will provide a plan based on its assessment of the intellectual property of Oncology Pharma and assist the company in targeting the first indication for use.ABOUT ONCOLOGY PHARMA, INCONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the “Company”) is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.FORWARD LOOKING STATEMENTSCertain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company’s financial position.CONTACTS:For additional Information, please contact the Oncology Pharma at:One Sansome Street, Suite 3500San Francisco, CA 94104Phone: 415-869-1038 Fax: 415-946-8801Email: info@oncology-pharma.comWebsite: www.oncology-pharma.com